Clinical trials: Arthritis,Rheumatoid
Rheumatoid Arthritis
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate and have had an inadequate response to a…
- Trial name
- OSKIRA - 3 (NCT01197755)
- Testing
- fostamatinib
- Where
- 135 sites in United States, Argentina and 14 more
- Volunteers
- 323 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis
This randomized, double-blind, parallel group study compares the efficacy and safety of subcutaneous (sc) versus intravenous (iv) administration of tocilizumab in participants with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT01194414
- Testing
- tocilizumab SC, tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
- Where
- 216 sites in United States, Argentina and 24 more
- Volunteers
- 1,262 people
- Sponsor
- Hoffmann-La Roche
Progressive Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
- Trial name
- NCT06025578
- Testing
- BMS-986278
- Where
- 459 sites in United States, Argentina and 33 more
- Volunteers
- 1,057 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis
This study will determine the efficacy, safety, and tolerability of denosumab (AMG 162) in the treatment of Rheumatoid Arthritis (RA).
- Trial name
- NCT00095498
- Testing
- denosumab
- Volunteers
- 227 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Treatment for Subjects With Active Rheumatoid Arthritis (RA)
The purpose of this study is to assess the safety of etanercept liquid administered once weekly to subjects with RA.
- Trial name
- NCT00110903
- Testing
- Etanercept Liquid
- Sponsor
- Amgen
Arthritis, Rheumatoid Arthritis
To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate
The primary objectives are to determine the relationship between blood levels of CDP6038 and suppression of C-reactive Protein (CRP) following single doses given as intravenous (IV) infusion or subcutaneous (SC) injection to…
- Trial name
- NCT01009242
- Testing
- CDP6038, CDP 6038 SC, Methotrexate
- Where
- 6 sites in United States, Germany
- Volunteers
- 40 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate
This study assessed the long-term safety and tolerability of ACZ885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of joint structure and bone mineral density, and…
- Trial name
- NCT00619905
- Testing
- ACZ885
- Where
- 10 sites in Germany, Netherlands and 1 more
- Volunteers
- 53 people
- Sponsor
- Novartis
Rheumatoid Arthritis
Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4
Olokizumab (OKZ) has been shown to reverse the inhibitory effect of IL-6 on the activity of Cytochrome P450 (CYP450) isozymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4/5 in vitro.
- Trial name
- NCT04246762
- Testing
- Olokizumab, Omeprazole, Caffeine
- Where
- 2 sites in Bulgaria, Moldova
- Volunteers
- 17 people
- Sponsor
- R-Pharm International, LLC
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis
This is a two-stage study of efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of various doses of levilimab when administered intravenously and subcutaneously to healthy subjects and subjects with active…
- Trial name
- NCT05800327
- Testing
- Levilimab
- Where
- Russia
- Volunteers
- 261 people, healthy volunteers welcome
- Sponsor
- Biocad
Rheumatoid Arthritis
Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056
The purpose of the study is to determine whether treatment with a single 800mg dose of AZD9056, a medication which has been developed as a possible treatment for Rheumatoid Arthritis, has an effect on the function of the retina
- Trial name
- NCT00700986
- Testing
- AZD9056
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment
To evaluate the inhibitory effect of progression, compared with placebo, in joint destruction by AMG 162 administered subcutaneously to rheumatoid arthritis participants.
- Trial name
- DESIRABLE (NCT01973569)
- Testing
- denosumab
- Where
- Japan
- Volunteers
- 679 people
- Sponsor
- Daiichi Sankyo
Rheumatoid Arthritis
An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.
This open-label, single arm study will investigate the safety, tolerability and efficacy of tocilizumab monotherapy, or combination therapy with non-biologic disease modifying antirheumatic drugs (DMARDs), in patients with severe…
- Trial name
- NCT00750880
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 282 sites in Australia, Austria and 23 more
- Volunteers
- 1,681 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).
The study will assess the efficacy and safety of PF-06438179 and infliximab in combination with methotrexate in subjects with active rheumatoid arthritis who have had an inadequate response to methotrexate.
- Trial name
- NCT02222493
- Testing
- PF-06438179, Infliximab
- Where
- 184 sites in United States, Australia and 26 more
- Volunteers
- 650 people
- Sponsor
- Pfizer
Active Rheumatoid Arthritis, Arthritis, Rheumatoid
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
Study to evaluate whether there is sustained remission and productivity in subjects with early rheumatoid arthritis started on etanercept plus methotrexate treatment.
- Conditions
- Active Rheumatoid Arthritis, Arthritis, Rheumatoid, Rheumatoid Arthritis
- Trial name
- NCT00913458
- Testing
- etanercept
- Where
- 59 sites in France, Germany and 11 more
- Volunteers
- 306 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice
The purpose of this study was to evaluate physical activity and its changes in participants with rheumatoid arthritis (RA) who were treated with adalimumab therapy in clinical practice.
- Trial name
- PACE (NCT01756235)
- Volunteers
- 462 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Xerostomia, Sjogren's Syndrome
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness
The primary objective of this clinical study is to determine the impact of P-552 oral rinse on salivary volume after administration of a single dose of P-552and versus vehicle rinse.
- Trial name
- NCT01369589
- Testing
- P-552
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Parion Sciences
Rheumatoid Arthritis, Pharmacokinetics of ASP2409
A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of single, ascending, intravenous (IV) doses of ASP2409 in patients with Rheumatoid Arthritis (RA) on methotrexate (MTX) and to evaluate…
- Trial name
- NCT02171143
- Testing
- ASP2409
- Where
- 10 sites in United States
- Volunteers
- 58 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Arthritis, Rheumatoid
Leflunomide EfficAcy Response Related to Dosing Regimen in Early Rheumatoid Arthritis
To assess the efficacy response rate at 3-months of two dosing regimen of leflunomide in DMARDs-naive patients presenting an early-RA using American College of Rheumatology 20% response rate.
- Trial name
- LEADER (NCT00596206)
- Testing
- leflunomide
- Where
- 5 sites in Czechia, Italy and 3 more
- Volunteers
- 124 people
- Sponsor
- Sanofi
Osteoarthritis, Rheumatoid Arthritis
Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns
The most common pain-relievers used by patients with rheumatic disorders are called non-steroidal anti-inflammatory drugs (NSAIDs).
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- CHARACTERIZE (NCT01511926)
- Where
- 96 sites in Belgium, Finland and 6 more
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.